US · Healthcare · Biotechnology
Analysts rate Adlai Nortye Ltd. American Depositary Shares a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $29.50.
| Fund | Stake |
|---|---|
| Cormorant Asset Management, LLC | 6.18% |
| VR Adviser, LLC | 4.99% |
| Balyasny Asset Management LLC | 4.75% |
| Point72 Asset Management, L.P. | 3.32% |
| MPM Oncology Impact Management LP | 3.01% |
| Perceptive Advisors LLC | 2.78% |
| Casdin Capital, LLC | 1.94% |
| ADAR1 Capital Management LLC | 1.58% |
| Document | Date |
|---|---|
| Report of foreign private issuer (6-K) · Q4 2026 HEADLINE NUMBERS • Adlai Nortye Group Ltd. filed a Form 6-K with the SEC for October 2026. • The filing was dated October 28, 2026, and relates to | 2026-10-28 |
| Report of foreign private issuer (6-K) · Q4 2026 BUSINESS & SEGMENT HIGHLIGHTS • Adlai Nortye Group Ltd. announced a clinical collaboration with Eli Lilly and Merck KGaA, Darmstadt, Germany. • The | 2026-10-15 |
| Report of foreign private issuer (6-K) · Q3 2026 OTHER NOTABLE POINTS • On September 30, 2026, Adlai Nortye Group Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission. • The compa | 2026-09-30 |
| Report of foreign private issuer (6-K) · Q3 2026 HEADLINE NUMBERS • Adlai Nortye Group Ltd. held an Extraordinary General Meeting (EGM) on September 30, 2026. • 40,433,365 ordinary shares were repr | 2026-09-30 |
| Report of foreign private issuer (6-K) · Q3 2026 HEADLINE NUMBERS • On September 8, 2026, Adlai Nortye announced that the first patient had been dosed in Australia in a clinical trial of AN4035. • | 2026-09-08 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Adlai Nortye will hold an Extraordinary General Meeting on September 30, 2026 at 10 a.m. Singapore time in Singapore. • Sharehold | 2026-08-26 |
| Report of foreign private issuer (6-K) · Q3 2026 HEADLINE NUMBERS • The document is the constitution of Adlai Nortye Group Ltd., registered in Singapore on July 29, 2026, under registration number 2 | 2026-08-19 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Revenue was US$13.1 million in 1H26, versus nil in 1H25. All revenue came from the AN9025 exclusive license agreement with Jiangsu | 2026-08-14 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Adlai Nortye Ltd. American Depositary Shares — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.